Oral L-Carnitine used to treat narcoleptic type 1 patient during pregnancy - A case report

Felipe Barros; Ana Carolina Rodrigues Aguilar; Sergio Tufik; Fernando Morgadinho Coelho

doi:10.5935/1984-0063.20180035

Sleep Science, Table of Contents

CC BY-NC-ND 4.0 · Sleep Sci 2018; 11(04): 215-216
DOI: 10.5935/1984-0063.20180035

CASE REPORT

Oral L-Carnitine used to treat narcoleptic type 1 patient during pregnancy - A case report

Authors

Felipe Barros

¹UNIFESP, Neurologia e Neurocirurgia - São Paulo - São Paulo - Brazil.
Ana Carolina Rodrigues Aguilar

²UNIFESP, Psicobiologia - São Paulo - São Paulo - Brazil.
Sergio Tufik

¹UNIFESP, Neurologia e Neurocirurgia - São Paulo - São Paulo - Brazil.
Fernando Morgadinho Coelho

¹UNIFESP, Neurologia e Neurocirurgia - São Paulo - São Paulo - Brazil.

²UNIFESP, Psicobiologia - São Paulo - São Paulo - Brazil.

Abstract

Narcolepsy type 1 is a sleep disorder characterized by excessive daytime sleepiness (EDS), sleep fragmentation, hypnagogic hallucinations, sleep paralysis, and cataplexy. Stimulant medications such as modafinil and amphetamines are the first-line medications for treating sleepiness. However, the management of narcolepsy during special circumstances of life such as pregnancy is complex. MMDM is a 34-year-old female with Narcolepsy type 1 treated with modafinil (400mg/d) and citalopram (20mg/d). Before she become pregnant, modafinil and citalopram were replaced for L-Carnitine 510mg/d with good outcome. She underwent an usual pregnancy and was submitted to a term cesarean delivery without child-birth complications. This is the first description of oral L-Carnitine such an alternative to treatment narcolepsy type 1 during pregnancy. Treat these patients is not easy but care narcolepsy pregnant is a challenging even bigger. In a disease without many treatment options, L-Carnitine can be used to treat daytime sleepiness during pregnancy in narcolepsy.

Narcolepsy - Pregnancy - L-Carnitine

Full Text

References

REFERENCES
1 Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18(2):78-105.
2 Maurovich-Horvat E, Kemlink D, Högl B, Frauscher B, Ehrmann L, Geisler P, et al.; European Narcolepsy Network. Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. J Sleep Res. 2013;22(5):496-512.
3 Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, et al. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PloS One. 2013;8(1):e53707.
4 Miyagawa T, Miyadera H, Tanaka S, Kawashima M, Shimada M, Honda Y, et al. Abnormally low serum acylcarnitine levels in narcolepsy patients. Sleep. 2011;34(3):349-53A.
5 Fonseca Hde A, Lopes DA, Pereira D, Sguillar DA, Lopes E, Behrens NS, et al. The use of citalopram for the treatment of cataplexy. Sleep Sci. 2014;7(1):50-2.
6 Romigi A, Liguori C, Izzi F, Albanese M, Marchi A, Mancini C, et al. Oral L-carnitine as treatment for narcolepsy without cataplexy during pregnancy: a case report. J Neurol Sci. 2015;348(1-2):282-3.
7 Andrade C. Adverse Gestational Outcomes Associated With Attention- Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy. J Clin Psychiatry. 2018;79(1).pii:18f12136.
8 Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9-18.
9 Calvo-Ferrandiz E, Peraita-Adrados R. Narcolepsy with cataplexy and pregnancy: a case-control study. J Sleep Res. 2018;27(2):268-72.